Proteins with Altered Levels in Plasma from Glioblastoma Patients as Revealed by iTRAQ-Based Quantitative Proteomic Analysis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Gautam, Poonam ^a   Nair, Sudha C ^a   Gupta, Manoj Kumar ^a   Sharma, Rakesh ^b   Polisetty, Ravindra Varma ^a   Uppin, Megha S ^c   Sundaram, Challa ^c   Puligopu, Aneel K ^c   Ankathi, Praveen ^c   Purohit, Aniruddh K ^c   Chandak, Giriraj R ^a   Harsha, H C ^b   Sirdeshmukh, Ravi ^a,b  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^b Institute of Bioinformatics   (India)

^c NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN B; CARNOSINASE 1; FERRITIN; FERRITIN LIGHT CHAIN; REGULATOR PROTEIN; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

APOFERRITINS; BRAIN NEOPLASMS; CALCIUM; CALGRANULIN B; CARNOSINE; CHROMATOGRAPHY, LIQUID; DIPEPTIDASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84866973317     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046153     Document Type: Article

References (52)

1. Stark AM, Nabavi A, Mehdorn HM, Blomer U, (2005) Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 63: 162-169.
2. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M, (2006) Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2: 494-503.
3. Schneider SW, Ludwig T, Tatenhorst L, Braune S, Oberleithner H, et al. (2004) Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol 107: 272-76.
4. Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, et al. (2011) Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol 13: 1244-51.
5. Jung CS, Foerch C, Schänzer A, Heck A, Plate KH, et al. (2007) Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130: 3336-41.
6. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, et al. (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12: 5698-704.
7. Quaranta M, Divella R, Daniele A, Tardo SD, Venneri MT, et al. (2007) Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. Tumori 93: 275-80.
8. Zhou M, Wiemels JL, Bracci PM, Wrensch MR, McCoy LS, et al. (2010) Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma. Cancer Res 70: 7534-42.
9. Reynés G, Vila V, Martín M, Parada A, Fleitas T, et al. (2011) Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 102: 35-41.
10. Kumar DM, Thota B, Shinde SV, Prasanna KV, Hegde AS, et al. (2010) Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. J Proteome Res 9: 5557-67.
11. Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, et al. (2008) Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem 54: 713-22.
12. Polisetty RV, Gautam P, Sharma R, Harsha HC, Nair SC, et al. (2012) LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signalling and other protein groups of regulatory functions. Mol Cell Proteomics 11(6): M111.013565.
13. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
14. Kwaan HC, McMahon B, (2009) The role of plasminogen-plasmin system in cancer. Cancer Treat Res 148: 43-66.
15. Nomura A, Chyou PH, Stemmermann GN, (1992) Association of serum ferritin levels with the risk of stomach cancer. Cancer Epidemiol Biomarkers Prev 1: 547-50.
16. Tolosano E, Altruda F, (2002) Hemopexin: structure, function, and regulation. DNA Cell Biol 21: 297-306.
17. Xu G, Hou CR, Jiang HW, Xiang CQ, Shi N, et al. (2010) Serum protein profiling to identify biomarkers for small renal cell carcinoma. Indian J Biochem Biophys 47: 211-18.
18. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N, et al. (1984) Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 19: 193-98.
19. Salmaggi A, Eoli M, Frigerio S, Ciusani E, Silvani A, et al. (1999) Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. Cancer Lett 146: 169-72.
20. Modlin IM, Gustafson BI, Moss SF, Pavel M, Tsolakis AV, et al. (2010) Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 17: 2427-43.
21. Belli SH, Oneto A, Aranda C, O'Connor JM, Domenichini E, et al. (2009) Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina. Acta Gastroenterol Latinoam. 39: 184-9.
22. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, et al. (2011) The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 40: 111-34.
23. Haapasalo J, Nordfors K, Järvelä S, Bragge H, Rantala I, et al. (2007) Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. Neuro Oncol 9: 308-13.
24. Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS, (2009) Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 7: 1756-70.
25. Lenney JF, Peppers SC, Kucera CM, Sjaastad O, (1983) Homocarnosinosis: lack of serum carnosinase is the defect probably responsible for elevated brain and CSF homocarnosine. Clin Chim Acta 132: 157-165.
26. Ozawa H, Nishida A, Mito T, Takashima S, (1994) Development of ferritin-positive cells in cerebrum of human brain. Pediatr Neurol 10: 44-8.
27. Maxim PE, Veltri RW, (1986) Serum ferritin as a tumor marker in patients with squamous cell carcinoma of the head and neck. Cancer 57: 305-11.
28. Sato Y, Honda Y, Asoh T, Oizumi K, Ohshima Y, et al. (1998) Cerebrospinal fluid ferritin in glioblastoma: evidence for tumor synthesis. J Neurooncol 40: 47-50.
29. Roth J, Burwinkel F, Vanden Bos C, Goebeler M, Vollmer E, et al. (1993) MRP8 and MRP14, S-100-like proteins associated with myeloid differentiation, are translocated to plasma membrane and intermediate filaments in a calcium-dependent manner. Blood 82: 1875-83.
30. Németh J, Angel P, Hess J, (2009) Dual Role of S100A8 and S100A9 in Inflammation-Associated Cancer. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 8: 329-36.
31. Gaunitz F, Hipkiss AR, (2012) Carnosine and cancer: a perspective. Amino Acids 43: 135-42.
32. Renner C, Zemitzsch N, Fuchs B, Geiger KD, Hermes M, et al. (2010) Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model. Mol Cancer 9: 2.
33. Schoen P, Everts H, de Boer T, van Oeveren W, (2003) Serum carnosinase activity in plasma and serum: validation of a method and values in cardiopulmonary bypass surgery. Clin Chem 49: 1930-2.
34. Wassif WS, Sherwood RA, Amir A, Idowu B, Summers B, et al. (1994) Serum carnosinase activities in central nervous system disorders. Clin Chim Acta 225: 57-64.
35. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, et al. (2009) Human Protein Reference Database-2009 update. Nucleic Acids Res 37: D767-72.
36. Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA, et al. (2010) Establishing the proteome of normal human cerebrospinal fluid. PLoS One 5: e10980.
37. Farrah T, Deutsch EW, Omenn GS, Campbell DS, Sun Z, et al. (2011) A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 10(9): M110.006353.
38. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
39. Polisetty RV, Gautam P, Sharma R, Harsha HC, Nair SC, et al. (2012) LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signalling and other protein groups of regulatory functions. Mol Cell Proteomics 11(6): M111.013565.
40. Haapasalo J, Nordfors K, Järvelä S, Bragge H, Rantala I, et al. (2007) Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. Neuro Oncol 9: 308-13.
41. Deininger MH, Meyermann R, Schluesener HJ, (2003) Expression and release of CD14 in astrocytic brain tumors. Acta Neuropathol 106: 271-7.
42. Donev K, Scheithauer BW, Rodriguez FJ, Jenkins S, (2010) Expression of diagnostic neuronal markers and outcome in glioblastoma. Neuropathol Appl Neurobiol 36: 411-21.
43. Khwaja FW, Nolen JD, Mendrinos SE, Lewis MM, Olson JJ, et al. (2006) Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 6: 6277-87.
44. Gasque P, Julen N, Ischenko AM, Picot C, Mauger C, et al. (1992) Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 149: 1381-7.
45. Rajcevic U, Petersen K, Knol JC, Loos M, Bougnaud S, et al. (2009) iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics 8: 2595-612.
46. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, et al. (2011) The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 25: 2594-609.
47. Järvelä S, Rantala I, Rodriguez A, Kallio H, Parkkila S, et al. (2010) Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors. BMC Cancer 10: 104.
48. Sloan KE, Stewart JK, Treloar AF, Matthews RT, Jay DG, (2005) CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res 65: 10930-7.
49. Mäenpää A, Kovanen PE, Paetau A, Jäáskeläinen J, Timonen T, (1997) Lymphocyte adhesion molecule ligands and extracellular matrix proteins in gliomas and normal brain: expression of VCAM-1 in gliomas. Acta Neuropathol 94: 216-25.
50. Gladson CL, Cheresh DA, (1991) Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 88: 1924-32.
51. McComb RD, Jones TR, Pizzo SV, Bigner DD, (1982) Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma. J Neuropathol Exp Neurol 41: 479-89.
52. Murakami M, Ushio Y, Morino Y, Ohta T, Matsukado Y, (1988) Immunohistochemical localization of apolipoprotein E in human glial neoplasms. J Clin Invest 82: 177-88.